This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Su, H. Articles by You, Q. Search for Related Content PubMed PubMed Citation Articles by Su, H. Articles by You, Q. Related Collections Therapeutics and Targets Therapeutics and Targets: Experimental Therapeutics– Small Molecules

Review

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

¹ Department of Medicinal Chemistry, China Pharmaceutical University, Jiangsu, People's Republic of China; and ² Dipartimento di Patologia generale, Seconda Università degli Studi di Napoli, Naples, Italy

Requests for reprints: Qidong You, Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, Jiangsu, 210009 People's Republic of China. Phone: 86-25-83141351; Fax: 86-25-83141351. E-mail: youqidong{at}gmail.com

Histone deacetylase (HDAC) catalyze deacetylation of acetylated lysine residues on histones and a growing number of nonhistone proteins including many transcription factors, playing an important role in the upstream control of gene transcription, cell cycle progression, and apoptosis. It has been wildly recognized that HDACs are promising targets for cancer therapy. At least 10 HDAC inhibitors are currently in clinical evaluation. However, none of them is practically isoform selective. More and more evidence suggests that acetylation modification occurring in 85% of eukaryotic proteins should be a general mechanism for altering protein structures or protein-protein interactions. Unselectively inhibiting the deacetylation activity of HDACs and the consequent modulation of the acetylation status of so many substrates might have multiple mechanisms of action in vivo, resulting in both therapeutic responses and unanticipated side effects. Lack of selectivity for the existing HDAC inhibitors is somewhat logical for the highly conserved residues in the catalytic site and the malleable structure in the rim of the active site of HDAC enzymes. For further advancements in the development of HDAC inhibitors, clues for selectivity will have to be considered. [Mol Cancer Ther 2008;7(5):1007–12]

Received 11/30/07; revised 2/ 4/08; accepted 2/20/08.